局部晚期宫颈癌放化疗联合图像引导自适应近距离放疗后迟发性显著患者报告症状的持续存在:EMBRACE研究报告
该研究基于EMBRACE多中心研究,分析局部晚期宫颈癌接受磁共振图像引导自适应近距离放疗后迟发性显著患者报告症状(LAPERS)的持续情况。741例有足够随访的患者中,LAPERS事件中位率为4.6%(范围0.0%阴道出血至20.4%疲乏),中位19%的症状患者表现为持续症状。在具有EORTC/CTCAE对应评估的症状中,仅12%的LAPERS事件伴有严重CTCAE事件,强调需区分短暂与持续症状。
要点
- LAPERS事件中位率4.6%,疲乏最高达20.4%,尿频、神经病变、失眠、更年期症状LAPERS率>10%。
- 中位19%的症状患者表现为持续症状,呕吐、便血、尿痛/灼烧、异常阴道出血LAPERS率<1%。
- 仅12%的LAPERS事件伴有严重CTCAE事件,多数持续症状无对应严重医生评估毒性。
核心结论
- 在局部晚期宫颈癌幸存者大样本中识别出持续症状(LAPERS事件)亚组。
- 多数LAPERS事件发生于无对应严重医生评估毒性的患者。
- 随访中需区分短暂与持续症状。
研究设计与样本
- 多中心EMBRACE研究,评估磁共振图像引导自适应近距离放疗。
- 使用EORTC-C30/CX24患者报告症状和CTCAE 3.0医生评估毒性,基线和定期随访评估。
- 1047例有EORTC数据的患者中741例有足够随访(基线及≥3次晚期随访)纳入分析,中位随访59个月(IQR 42-70个月)。
主要发现
- 所有症状中LAPERS事件比例中位4.6%(范围0.0%阴道出血至20.4%疲乏)。
- 尿频、神经病变、疲乏、失眠和更年期症状LAPERS率>10%;呕吐、便血、尿痛/灼烧和异常阴道出血LAPERS率<1%。
- 中位19%的症状患者(IQR 8.0%-28.5%)显示持续长期症状(LAPERS事件)。
- 在具有EORTC/CTCAE对应评估的症状中,12%的LAPERS事件伴有严重CTCAE事件。
关键数值与推荐
- LAPERS事件定义:至少一半评估中存在显著EORTC症状(相当多/非常多)且超出基线状况进展。
- LAPERS率与显著症状粗发生率的比值代表有持续症状的症状患者比例。
- 对9个有EORTC/CTCAE对应评估的症状评估LAPERS与严重毒性事件(3-5级)的重叠。
临床怎么用
- 局部晚期宫颈癌幸存者随访中应关注持续症状,而不仅依赖医生评估的严重毒性。
- 对疲乏、尿频、神经病变、失眠和更年期症状等LAPERS率较高的症状应加强患者报告症状监测。
局限性
- 仅纳入有足够EORTC随访(基线及≥3次晚期随访)的患者,可能存在选择偏倚。
- LAPERS定义基于至少一半评估中显著症状且超出基线,定义可能影响结果。
- CTCAE 3.0版本较旧,与当前版本可能存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This report describes the persistence of late substantial treatment-related patient-reported symptoms (LAPERS) in the multi-institutional EMBRACE study on magnetic resonance image guided adaptive brachytherapy in locally advanced cervical cancer (LACC). METHODS AND MATERIALS: Patient-reported symptoms (European Organization for Research and Treatment of Cancer [EORTC]-C30/CX24) and physician-assessed morbidity (Common Terminology Criteria for Adverse Events [CTCAE], version 3.0) were assessed at baseline and regular timepoints during follow-up. Patients with sufficient EORTC follow-up (baseline and ≥3 late follow-up visits) were analyzed. LAPERS events were defined as the presence of substantial EORTC symptoms (quite a bit/very much) for at least half of the assessments (persistence) and progression beyond baseline condition (treatment-related). For each EORTC symptom, the ratio between LAPERS rates and crude incidence rates of substantial symptoms was calculated to represent the proportion of symptomatic patients with persisting symptoms. For 9 symptoms with a corresponding EORTC/CTCAE assessment, the overlap of LAPERS and severe morbidity events (grades 3-5) was evaluated. RESULTS: Of 1047 patients with EORTC available, 741 had sufficient follow-up for the LAPERS analyses. The median follow-up was 59 months (interquartile range, 42-70 months). Across all symptoms, the proportion of patients with LAPERS events (LAPERS rates) was in median 4.6% (range, 0.0% vaginal bleeding to 20.4% tiredness). Urinary frequency, neuropathy, fatigue, insomnia, and menopausal symptoms revealed LAPERS rates of >10%. Vomiting, blood in stool, urinary pain/burning, and abnormal vaginal bleeding displayed LAPERS rates of <1%. A median of 19% of symptomatic patients (interquartile range, 8.0%-28.5%) showed persistent long-term symptoms (LAPERS events). In symptoms with a corresponding EORTC/CTCAE assessment, 12% of LAPERS events were accompanied by a severe CTCAE event. CONCLUSIONS: Within this large cohort of survivors of LACC, a subgroup of patients with persistent symptoms (LAPERS events) was identified. For symptoms with a corresponding EORTC/CTCAE assessment, the vast majority of LAPERS events occurred in patients without corresponding severe physician-assessed morbidity. These findings emphasize the importance of distinguishing between transient and persisting symptoms in the aftercare of LACC survivors.
引用
- Vittrup AS, Tanderup K, Bentzen SM, et al. Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. Int J Radiat Oncol Biol Phys. 2020. PMID: 32853710. doi:10.1016/j.ijrobp.2020.08.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。